20/20 BioLabs and ROKIT Healthcare Enter Licensing Agreement
On March 24, 2026, 20/20 BioLabs, Inc., an early market entrant in AI-powered blood tests for detecting cancers and chronic diseases, announced an exclusive U.S. technology license and access agreement with ROKIT Healthcare Inc., according to GlobeNewswire PE. Under the agreement, 20/20 will integrate ROKIT’s proprietary chronic kidney disease (CKD) prediction algorithm into its Longevity Platform, expanding its suite of biomarker-based disease-risk assessment tools. ROKIT agreed to reimburse 20/20 for one-third of mutually agreed sales and marketing expenses in exchange for a running royalty on net sales of the combined product.
Details of the Integration
The agreement involves adding CKD prediction capabilities to 20/20’s OneTest for Longevity, which uses biomarkers like CRP to measure systemic inflammation. Clinical evidence indicates that patients with lower inflammation levels respond better to regenerative therapies, such as ROKIT’s 3-D bio-printed tissue patches for burns, CKD, and heart failure. Wonkyung Choi, Vice President of R&D at ROKIT Healthcare, stated that patients treated with these patches may achieve better outcomes by lowering inflammation through 20/20’s tools for dietary and lifestyle changes.
Future Collaboration and Market Expansion
The companies anticipate negotiating a separate agreement that would grant ROKIT exclusive rights to commercialize 20/20’s longevity platform in Korea and potentially other East Asian markets. This move aims to enhance 20/20’s position in the longevity-analytics sector, where chronic kidney disease affects more than 35 million Americans and early detection is crucial for slowing progression. Jonathan Cohen, President and CEO of 20/20 BioLabs, described the agreement as a validation of their platform strategy, according to GlobeNewswire PE.
Implications for the Sector
As a widely-known context, the biotechnology industry often sees partnerships like this to advance personalized medicine, though this specific deal focuses on integrating predictive algorithms for better disease management. The addition of ROKIT’s technology to 20/20’s platform provides earlier insights and personalized risk assessments for individuals and healthcare providers.
